Stephen Waldo
Concepts (419)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Percutaneous Coronary Intervention | 77 | 2025 | 549 | 17.810 |
Why?
| | Coronary Artery Disease | 45 | 2025 | 747 | 10.290 |
Why?
| | United States Department of Veterans Affairs | 33 | 2025 | 773 | 5.520 |
Why?
| | Coronary Angiography | 31 | 2025 | 328 | 3.510 |
Why?
| | Peripheral Arterial Disease | 25 | 2020 | 506 | 3.160 |
Why?
| | Myocardial Infarction | 29 | 2025 | 1210 | 3.130 |
Why?
| | Endovascular Procedures | 18 | 2020 | 389 | 2.920 |
Why?
| | Femoral Artery | 13 | 2022 | 190 | 2.640 |
Why?
| | Acute Coronary Syndrome | 8 | 2025 | 297 | 2.610 |
Why?
| | Treatment Outcome | 91 | 2025 | 11741 | 2.540 |
Why?
| | Veterans | 18 | 2025 | 1625 | 2.520 |
Why?
| | Vascular Calcification | 9 | 2022 | 110 | 2.310 |
Why?
| | Veterans Health | 7 | 2025 | 189 | 2.220 |
Why?
| | Stents | 21 | 2019 | 561 | 2.150 |
Why?
| | ST Elevation Myocardial Infarction | 6 | 2022 | 64 | 2.070 |
Why?
| | Popliteal Artery | 11 | 2020 | 62 | 2.060 |
Why?
| | Atherectomy | 11 | 2022 | 37 | 1.890 |
Why?
| | Myocardial Ischemia | 6 | 2025 | 285 | 1.890 |
Why?
| | Risk Factors | 70 | 2025 | 10857 | 1.860 |
Why?
| | Coronary Artery Bypass | 8 | 2025 | 268 | 1.850 |
Why?
| | Registries | 28 | 2023 | 2401 | 1.810 |
Why?
| | United States | 64 | 2026 | 16065 | 1.730 |
Why?
| | Ischemia | 11 | 2020 | 422 | 1.710 |
Why?
| | Time Factors | 52 | 2025 | 7107 | 1.660 |
Why?
| | Atherectomy, Coronary | 5 | 2022 | 10 | 1.650 |
Why?
| | Aged | 89 | 2026 | 26096 | 1.600 |
Why?
| | Risk Assessment | 29 | 2025 | 3740 | 1.590 |
Why?
| | Platelet Aggregation Inhibitors | 8 | 2025 | 499 | 1.530 |
Why?
| | Radial Artery | 7 | 2022 | 75 | 1.500 |
Why?
| | Lower Extremity | 4 | 2018 | 440 | 1.500 |
Why?
| | Angioplasty, Balloon, Coronary | 6 | 2017 | 156 | 1.480 |
Why?
| | Time-to-Treatment | 5 | 2024 | 250 | 1.450 |
Why?
| | Hospitals, Veterans | 5 | 2025 | 258 | 1.350 |
Why?
| | Middle Aged | 82 | 2025 | 36126 | 1.330 |
Why?
| | Humans | 160 | 2026 | 145140 | 1.290 |
Why?
| | Cardiovascular Agents | 7 | 2023 | 166 | 1.290 |
Why?
| | Non-ST Elevated Myocardial Infarction | 3 | 2020 | 26 | 1.240 |
Why?
| | Hospital Mortality | 13 | 2025 | 1038 | 1.200 |
Why?
| | Biological Products | 2 | 2023 | 257 | 1.200 |
Why?
| | Male | 103 | 2026 | 72664 | 1.170 |
Why?
| | Coronary Restenosis | 4 | 2017 | 22 | 1.150 |
Why?
| | Coronary Vessels | 7 | 2025 | 246 | 1.150 |
Why?
| | Angioplasty, Balloon | 9 | 2020 | 94 | 1.130 |
Why?
| | Female | 97 | 2026 | 78636 | 1.050 |
Why?
| | Myocardial Revascularization | 3 | 2019 | 85 | 1.040 |
Why?
| | Access to Information | 2 | 2019 | 47 | 1.020 |
Why?
| | Retrospective Studies | 54 | 2026 | 17247 | 1.010 |
Why?
| | Catheterization, Peripheral | 2 | 2019 | 120 | 0.990 |
Why?
| | Stroke Volume | 4 | 2026 | 653 | 0.940 |
Why?
| | Surgical Procedures, Operative | 3 | 2025 | 271 | 0.910 |
Why?
| | Exercise Test | 3 | 2025 | 626 | 0.900 |
Why?
| | Angina, Stable | 3 | 2022 | 18 | 0.890 |
Why?
| | Patient Readmission | 9 | 2025 | 769 | 0.880 |
Why?
| | Eligibility Determination | 1 | 2025 | 72 | 0.850 |
Why?
| | Coated Materials, Biocompatible | 6 | 2020 | 65 | 0.840 |
Why?
| | Natural Language Processing | 1 | 2025 | 106 | 0.830 |
Why?
| | Quality Improvement | 5 | 2025 | 1293 | 0.820 |
Why?
| | Quality of Health Care | 3 | 2025 | 692 | 0.810 |
Why?
| | Delivery of Health Care, Integrated | 2 | 2025 | 299 | 0.810 |
Why?
| | Cardiology | 4 | 2022 | 360 | 0.800 |
Why?
| | Myocardial Reperfusion | 2 | 2013 | 56 | 0.790 |
Why?
| | Community Health Services | 1 | 2025 | 231 | 0.780 |
Why?
| | Cardiac Catheterization | 5 | 2025 | 558 | 0.770 |
Why?
| | Vascular Patency | 14 | 2020 | 121 | 0.750 |
Why?
| | Ventricular Function, Left | 3 | 2021 | 539 | 0.750 |
Why?
| | Chickens | 1 | 2023 | 179 | 0.740 |
Why?
| | Coronary Thrombosis | 4 | 2015 | 25 | 0.710 |
Why?
| | Heart Arrest | 3 | 2017 | 408 | 0.710 |
Why?
| | Vascular Access Devices | 5 | 2020 | 30 | 0.710 |
Why?
| | Elective Surgical Procedures | 2 | 2020 | 202 | 0.700 |
Why?
| | Psoriasis | 1 | 2023 | 115 | 0.700 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 5 | 2023 | 442 | 0.700 |
Why?
| | Healthcare Disparities | 3 | 2024 | 731 | 0.690 |
Why?
| | California | 18 | 2019 | 471 | 0.690 |
Why?
| | Practice Patterns, Physicians' | 7 | 2025 | 1365 | 0.670 |
Why?
| | Anemia | 2 | 2022 | 190 | 0.660 |
Why?
| | Coronary Occlusion | 2 | 2023 | 20 | 0.660 |
Why?
| | Aged, 80 and over | 23 | 2025 | 8318 | 0.660 |
Why?
| | Heart Failure, Systolic | 1 | 2021 | 26 | 0.660 |
Why?
| | Patient Selection | 1 | 2025 | 733 | 0.650 |
Why?
| | Drug-Eluting Stents | 6 | 2017 | 88 | 0.620 |
Why?
| | Hospitals, Community | 1 | 2020 | 67 | 0.620 |
Why?
| | Assisted Circulation | 1 | 2019 | 26 | 0.610 |
Why?
| | Paclitaxel | 2 | 2019 | 256 | 0.600 |
Why?
| | Hemorrhage | 5 | 2022 | 822 | 0.600 |
Why?
| | Electronic Health Records | 3 | 2025 | 1188 | 0.600 |
Why?
| | Hemostatic Techniques | 1 | 2020 | 52 | 0.600 |
Why?
| | Cardiovascular Diseases | 4 | 2025 | 2183 | 0.590 |
Why?
| | Embolic Protection Devices | 1 | 2019 | 12 | 0.580 |
Why?
| | Quality Indicators, Health Care | 4 | 2025 | 336 | 0.580 |
Why?
| | Saphenous Vein | 1 | 2019 | 37 | 0.580 |
Why?
| | Intra-Aortic Balloon Pumping | 1 | 2019 | 19 | 0.580 |
Why?
| | Graft Occlusion, Vascular | 1 | 2019 | 40 | 0.570 |
Why?
| | Heart Failure | 7 | 2026 | 2324 | 0.570 |
Why?
| | Postoperative Hemorrhage | 1 | 2020 | 105 | 0.570 |
Why?
| | Databases, Factual | 11 | 2025 | 1488 | 0.560 |
Why?
| | Cardiac Surgical Procedures | 2 | 2022 | 608 | 0.550 |
Why?
| | Postoperative Complications | 5 | 2025 | 2961 | 0.550 |
Why?
| | Fibrinolytic Agents | 2 | 2018 | 297 | 0.550 |
Why?
| | Electrocardiography | 4 | 2015 | 664 | 0.550 |
Why?
| | Arterial Occlusive Diseases | 1 | 2018 | 90 | 0.530 |
Why?
| | Arm | 1 | 2018 | 110 | 0.530 |
Why?
| | Peripheral Vascular Diseases | 1 | 2018 | 104 | 0.530 |
Why?
| | Odds Ratio | 8 | 2021 | 1082 | 0.530 |
Why?
| | Thromboembolism | 1 | 2018 | 129 | 0.510 |
Why?
| | Cerebrovascular Disorders | 1 | 2018 | 104 | 0.510 |
Why?
| | Kaplan-Meier Estimate | 12 | 2020 | 968 | 0.510 |
Why?
| | Limb Salvage | 7 | 2019 | 73 | 0.500 |
Why?
| | Propensity Score | 6 | 2024 | 374 | 0.500 |
Why?
| | Renal Artery Obstruction | 1 | 2017 | 30 | 0.500 |
Why?
| | Embolism | 1 | 2017 | 48 | 0.490 |
Why?
| | Renal Artery | 1 | 2017 | 43 | 0.490 |
Why?
| | Research Report | 1 | 2017 | 86 | 0.490 |
Why?
| | Aspirin | 2 | 2019 | 406 | 0.490 |
Why?
| | Contrast Media | 4 | 2025 | 497 | 0.480 |
Why?
| | Hospitals | 4 | 2023 | 732 | 0.480 |
Why?
| | Transcatheter Aortic Valve Replacement | 3 | 2025 | 153 | 0.470 |
Why?
| | Catheterization | 3 | 2021 | 183 | 0.460 |
Why?
| | Coronary Stenosis | 5 | 2020 | 40 | 0.450 |
Why?
| | Iliac Artery | 4 | 2019 | 55 | 0.440 |
Why?
| | Hypertension, Pulmonary | 5 | 2025 | 1955 | 0.420 |
Why?
| | Disclosure | 1 | 2015 | 84 | 0.420 |
Why?
| | Hospitalization | 4 | 2025 | 2458 | 0.420 |
Why?
| | Risk Reduction Behavior | 1 | 2016 | 217 | 0.420 |
Why?
| | Cell Separation | 1 | 2015 | 304 | 0.400 |
Why?
| | Atherosclerosis | 3 | 2019 | 409 | 0.400 |
Why?
| | Survival Rate | 7 | 2026 | 2087 | 0.400 |
Why?
| | Depressive Disorder | 1 | 2017 | 372 | 0.400 |
Why?
| | Thrombectomy | 2 | 2014 | 78 | 0.400 |
Why?
| | Cohort Studies | 10 | 2023 | 5988 | 0.390 |
Why?
| | Cardiologists | 2 | 2025 | 45 | 0.380 |
Why?
| | Vascular Surgical Procedures | 1 | 2016 | 343 | 0.370 |
Why?
| | Disease Management | 1 | 2017 | 651 | 0.370 |
Why?
| | Predictive Value of Tests | 9 | 2025 | 2115 | 0.370 |
Why?
| | Acute Kidney Injury | 5 | 2025 | 872 | 0.370 |
Why?
| | Peer Review | 2 | 2025 | 47 | 0.360 |
Why?
| | Incidence | 8 | 2025 | 2915 | 0.360 |
Why?
| | HIV | 1 | 2013 | 251 | 0.350 |
Why?
| | Logistic Models | 6 | 2017 | 2133 | 0.350 |
Why?
| | Intermittent Claudication | 3 | 2017 | 122 | 0.340 |
Why?
| | Attitude of Health Personnel | 1 | 2019 | 1186 | 0.340 |
Why?
| | Hypothermia | 1 | 2011 | 53 | 0.330 |
Why?
| | Hemodynamics | 5 | 2026 | 1115 | 0.330 |
Why?
| | Out-of-Hospital Cardiac Arrest | 2 | 2024 | 121 | 0.320 |
Why?
| | Cause of Death | 3 | 2023 | 470 | 0.320 |
Why?
| | Stroke | 7 | 2025 | 1270 | 0.310 |
Why?
| | Severity of Illness Index | 8 | 2025 | 2928 | 0.310 |
Why?
| | Aortic Valve Stenosis | 2 | 2025 | 255 | 0.300 |
Why?
| | Constriction, Pathologic | 9 | 2020 | 248 | 0.290 |
Why?
| | Mentoring | 2 | 2023 | 165 | 0.290 |
Why?
| | Proportional Hazards Models | 9 | 2023 | 1325 | 0.290 |
Why?
| | Peptide Fragments | 2 | 2015 | 693 | 0.290 |
Why?
| | Chi-Square Distribution | 4 | 2018 | 527 | 0.290 |
Why?
| | Mortality | 3 | 2020 | 378 | 0.280 |
Why?
| | Endothelial Cells | 1 | 2015 | 873 | 0.280 |
Why?
| | Punctures | 2 | 2019 | 41 | 0.280 |
Why?
| | Angiography | 6 | 2020 | 208 | 0.270 |
Why?
| | Laser Therapy | 2 | 2019 | 142 | 0.260 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2008 | 109 | 0.260 |
Why?
| | Carotid Stenosis | 2 | 2018 | 106 | 0.250 |
Why?
| | Myocardial Perfusion Imaging | 2 | 2019 | 50 | 0.250 |
Why?
| | Cardiac Output, High | 1 | 2026 | 1 | 0.240 |
Why?
| | Recurrence | 9 | 2019 | 1134 | 0.240 |
Why?
| | Sex Factors | 5 | 2025 | 2099 | 0.240 |
Why?
| | Emergency Medical Services | 1 | 2013 | 684 | 0.240 |
Why?
| | Follow-Up Studies | 7 | 2026 | 5411 | 0.240 |
Why?
| | Multivariate Analysis | 5 | 2017 | 1546 | 0.230 |
Why?
| | Ventricular Dysfunction, Left | 2 | 2021 | 393 | 0.230 |
Why?
| | Macrophages | 3 | 2008 | 1500 | 0.230 |
Why?
| | Acute Disease | 3 | 2017 | 1035 | 0.220 |
Why?
| | Purinergic P2Y Receptor Antagonists | 2 | 2023 | 71 | 0.220 |
Why?
| | HIV Infections | 3 | 2023 | 3186 | 0.220 |
Why?
| | Cytochrome P-450 CYP2C19 | 1 | 2025 | 26 | 0.220 |
Why?
| | Ultrasonography, Interventional | 2 | 2025 | 165 | 0.220 |
Why?
| | Peer Review, Health Care | 1 | 2025 | 4 | 0.220 |
Why?
| | Patient Discharge | 3 | 2022 | 991 | 0.220 |
Why?
| | Renal Insufficiency, Chronic | 2 | 2023 | 661 | 0.220 |
Why?
| | Chest Pain | 3 | 2022 | 99 | 0.210 |
Why?
| | Chemokine CXCL12 | 1 | 2025 | 86 | 0.210 |
Why?
| | Tomography, Optical Coherence | 2 | 2025 | 271 | 0.210 |
Why?
| | Travel | 1 | 2025 | 136 | 0.210 |
Why?
| | Comorbidity | 5 | 2020 | 1657 | 0.210 |
Why?
| | Pancreas | 2 | 2004 | 341 | 0.210 |
Why?
| | Prosthesis Failure | 2 | 2016 | 125 | 0.200 |
Why?
| | Health Services Accessibility | 2 | 2025 | 1099 | 0.200 |
Why?
| | Hypertension, Portal | 1 | 2024 | 66 | 0.200 |
Why?
| | Hypothermia, Induced | 1 | 2024 | 95 | 0.190 |
Why?
| | Coronary Circulation | 2 | 2014 | 134 | 0.190 |
Why?
| | Fractional Flow Reserve, Myocardial | 2 | 2020 | 10 | 0.190 |
Why?
| | Biological Therapy | 1 | 2023 | 28 | 0.190 |
Why?
| | Heart Valve Prosthesis Implantation | 1 | 2025 | 198 | 0.190 |
Why?
| | Cross-Sectional Studies | 6 | 2022 | 5886 | 0.190 |
Why?
| | New York | 3 | 2017 | 128 | 0.180 |
Why?
| | Work Engagement | 1 | 2022 | 14 | 0.180 |
Why?
| | Prognosis | 6 | 2021 | 4310 | 0.180 |
Why?
| | Chronic Disease | 5 | 2023 | 1806 | 0.180 |
Why?
| | Leukocytes | 1 | 2003 | 296 | 0.170 |
Why?
| | Technology Transfer | 1 | 2021 | 9 | 0.170 |
Why?
| | Clinical Decision-Making | 1 | 2025 | 362 | 0.170 |
Why?
| | Social Class | 1 | 2023 | 264 | 0.170 |
Why?
| | Critical Illness | 8 | 2020 | 899 | 0.170 |
Why?
| | Shock, Cardiogenic | 2 | 2021 | 65 | 0.160 |
Why?
| | Angina Pectoris | 1 | 2020 | 75 | 0.160 |
Why?
| | Aftercare | 1 | 2022 | 222 | 0.160 |
Why?
| | Mandatory Reporting | 2 | 2017 | 45 | 0.160 |
Why?
| | Thrombocytopenia | 1 | 2022 | 204 | 0.150 |
Why?
| | Anticoagulants | 2 | 2016 | 748 | 0.150 |
Why?
| | Massachusetts | 2 | 2017 | 180 | 0.150 |
Why?
| | Genome-Wide Association Study | 2 | 2025 | 1376 | 0.150 |
Why?
| | Delivery of Health Care | 2 | 2023 | 946 | 0.150 |
Why?
| | Patient Care Team | 1 | 2025 | 696 | 0.150 |
Why?
| | Echocardiography, Stress | 1 | 2019 | 29 | 0.150 |
Why?
| | Vascular Resistance | 1 | 2020 | 369 | 0.140 |
Why?
| | Health Facilities | 1 | 2019 | 85 | 0.140 |
Why?
| | Referral and Consultation | 1 | 2025 | 862 | 0.140 |
Why?
| | Intraoperative Period | 1 | 2019 | 69 | 0.140 |
Why?
| | Ambulatory Surgical Procedures | 1 | 2019 | 79 | 0.140 |
Why?
| | Heart | 1 | 2022 | 626 | 0.140 |
Why?
| | Fluid Therapy | 1 | 2020 | 154 | 0.140 |
Why?
| | Socioeconomic Factors | 1 | 2023 | 1321 | 0.140 |
Why?
| | Centralized Hospital Services | 1 | 2018 | 6 | 0.140 |
Why?
| | Thrombosis | 1 | 2022 | 401 | 0.140 |
Why?
| | Colorado | 8 | 2019 | 4538 | 0.140 |
Why?
| | Angioplasty, Balloon, Laser-Assisted | 1 | 2017 | 1 | 0.140 |
Why?
| | Secondary Prevention | 1 | 2019 | 251 | 0.140 |
Why?
| | Biomarkers | 4 | 2017 | 4282 | 0.130 |
Why?
| | Angioplasty | 1 | 2018 | 50 | 0.130 |
Why?
| | Pregnancy-Associated Plasma Protein-A | 1 | 2017 | 14 | 0.130 |
Why?
| | Perception | 1 | 2021 | 377 | 0.130 |
Why?
| | Disease-Free Survival | 5 | 2017 | 766 | 0.130 |
Why?
| | Cardiac Catheters | 1 | 2017 | 16 | 0.130 |
Why?
| | Transportation of Patients | 1 | 2018 | 65 | 0.130 |
Why?
| | Diabetes Mellitus, Type 2 | 2 | 2023 | 2578 | 0.130 |
Why?
| | Rosuvastatin Calcium | 1 | 2017 | 21 | 0.130 |
Why?
| | Perioperative Care | 1 | 2020 | 231 | 0.130 |
Why?
| | Macrophage Colony-Stimulating Factor | 2 | 2008 | 20 | 0.130 |
Why?
| | ADAMTS13 Protein | 1 | 2017 | 7 | 0.130 |
Why?
| | Pulmonary Artery | 1 | 2023 | 1126 | 0.130 |
Why?
| | Algorithms | 2 | 2017 | 1845 | 0.130 |
Why?
| | Computer Simulation | 1 | 2021 | 1002 | 0.130 |
Why?
| | Neck | 1 | 2017 | 108 | 0.130 |
Why?
| | Thrombotic Microangiopathies | 1 | 2017 | 19 | 0.130 |
Why?
| | Ankle Brachial Index | 1 | 2017 | 41 | 0.130 |
Why?
| | Risk | 2 | 2019 | 916 | 0.120 |
Why?
| | Suction | 2 | 2014 | 32 | 0.120 |
Why?
| | Policy Making | 1 | 2017 | 83 | 0.120 |
Why?
| | Reproducibility of Results | 5 | 2025 | 3410 | 0.120 |
Why?
| | Clinical Competence | 1 | 2025 | 1240 | 0.120 |
Why?
| | Flow Cytometry | 2 | 2015 | 1159 | 0.120 |
Why?
| | Aortic Valve | 1 | 2019 | 364 | 0.120 |
Why?
| | Health Services Needs and Demand | 1 | 2018 | 279 | 0.120 |
Why?
| | Boston | 1 | 2016 | 93 | 0.120 |
Why?
| | Academic Medical Centers | 2 | 2016 | 552 | 0.110 |
Why?
| | Adult | 7 | 2024 | 40665 | 0.110 |
Why?
| | Dyslipidemias | 1 | 2017 | 184 | 0.110 |
Why?
| | Pandemics | 2 | 2021 | 1703 | 0.110 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 2 | 2007 | 207 | 0.110 |
Why?
| | Burnout, Professional | 1 | 2022 | 486 | 0.110 |
Why?
| | Cholesterol | 2 | 2008 | 406 | 0.110 |
Why?
| | Gene Expression Profiling | 2 | 2015 | 1763 | 0.110 |
Why?
| | Contraindications | 1 | 2014 | 90 | 0.110 |
Why?
| | Aortic Diseases | 1 | 2016 | 125 | 0.110 |
Why?
| | Antithrombins | 1 | 2015 | 71 | 0.110 |
Why?
| | Models, Cardiovascular | 1 | 2015 | 195 | 0.100 |
Why?
| | Collateral Circulation | 1 | 2014 | 20 | 0.100 |
Why?
| | Prevalence | 2 | 2019 | 2855 | 0.100 |
Why?
| | Heparin | 1 | 2015 | 246 | 0.100 |
Why?
| | Observer Variation | 3 | 2025 | 356 | 0.100 |
Why?
| | Prospective Studies | 3 | 2020 | 8035 | 0.100 |
Why?
| | Incidental Findings | 1 | 2013 | 81 | 0.100 |
Why?
| | Diabetes Mellitus | 2 | 2018 | 1092 | 0.090 |
Why?
| | Primary Prevention | 1 | 2014 | 218 | 0.090 |
Why?
| | Resuscitation | 1 | 2015 | 310 | 0.090 |
Why?
| | Smoking Cessation | 1 | 2016 | 437 | 0.090 |
Why?
| | Coronary Disease | 1 | 2014 | 381 | 0.090 |
Why?
| | Trazodone | 1 | 2011 | 2 | 0.090 |
Why?
| | Antimanic Agents | 1 | 2011 | 19 | 0.090 |
Why?
| | Glucagon-Like Peptide-1 Receptor | 2 | 2023 | 88 | 0.090 |
Why?
| | Lithium | 1 | 2011 | 40 | 0.090 |
Why?
| | Triazines | 1 | 2011 | 49 | 0.080 |
Why?
| | Laboratories | 2 | 2022 | 110 | 0.080 |
Why?
| | American Heart Association | 2 | 2022 | 357 | 0.080 |
Why?
| | Prosthesis Design | 3 | 2017 | 354 | 0.080 |
Why?
| | Benzodiazepines | 1 | 2011 | 168 | 0.080 |
Why?
| | Decision Support Techniques | 1 | 2014 | 472 | 0.080 |
Why?
| | Age Factors | 4 | 2019 | 3338 | 0.070 |
Why?
| | Cell Differentiation | 2 | 2008 | 2040 | 0.070 |
Why?
| | Lipoproteins, LDL | 2 | 2007 | 119 | 0.070 |
Why?
| | Anticonvulsants | 1 | 2011 | 246 | 0.070 |
Why?
| | Bipolar Disorder | 1 | 2011 | 275 | 0.070 |
Why?
| | MicroRNAs | 1 | 2015 | 686 | 0.070 |
Why?
| | Depression | 1 | 2018 | 1537 | 0.070 |
Why?
| | Pinocytosis | 1 | 2007 | 6 | 0.070 |
Why?
| | Ultrasonography, Doppler, Duplex | 2 | 2017 | 40 | 0.060 |
Why?
| | Monocytes | 2 | 2007 | 537 | 0.060 |
Why?
| | Area Under Curve | 1 | 2008 | 329 | 0.060 |
Why?
| | Animals | 4 | 2025 | 37952 | 0.060 |
Why?
| | Seizures | 1 | 2011 | 482 | 0.060 |
Why?
| | Fluorescent Antibody Technique | 1 | 2008 | 365 | 0.060 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2008 | 161 | 0.060 |
Why?
| | Adrenergic beta-Antagonists | 2 | 2019 | 252 | 0.060 |
Why?
| | Drug Overdose | 1 | 2011 | 374 | 0.060 |
Why?
| | Phenotype | 2 | 2021 | 3138 | 0.060 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2025 | 2136 | 0.060 |
Why?
| | ROC Curve | 1 | 2008 | 617 | 0.060 |
Why?
| | Inflammation | 3 | 2008 | 2876 | 0.060 |
Why?
| | Equipment Design | 2 | 2018 | 525 | 0.060 |
Why?
| | Shock | 2 | 2004 | 109 | 0.060 |
Why?
| | Polymerase Chain Reaction | 1 | 2008 | 1039 | 0.050 |
Why?
| | Program Evaluation | 2 | 2019 | 943 | 0.050 |
Why?
| | Ventricular Fibrillation | 1 | 2024 | 64 | 0.050 |
Why?
| | Health Plan Implementation | 1 | 2025 | 141 | 0.050 |
Why?
| | Survival Analysis | 2 | 2020 | 1371 | 0.050 |
Why?
| | Lipid Metabolism | 1 | 2008 | 529 | 0.050 |
Why?
| | Trypsin | 1 | 2004 | 75 | 0.050 |
Why?
| | Exercise | 1 | 2016 | 2191 | 0.050 |
Why?
| | Amylases | 1 | 2003 | 18 | 0.050 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2004 | 130 | 0.050 |
Why?
| | Chymotrypsin | 1 | 2003 | 23 | 0.050 |
Why?
| | Ezetimibe | 1 | 2023 | 24 | 0.050 |
Why?
| | Length of Stay | 2 | 2019 | 1348 | 0.050 |
Why?
| | Tissue Distribution | 1 | 2003 | 335 | 0.050 |
Why?
| | Tachycardia, Ventricular | 1 | 2024 | 180 | 0.050 |
Why?
| | Drug Therapy, Combination | 2 | 2016 | 1043 | 0.050 |
Why?
| | Hypoglycemic Agents | 2 | 2023 | 1393 | 0.050 |
Why?
| | Polymorphism, Genetic | 1 | 2025 | 614 | 0.050 |
Why?
| | Glucagon-Like Peptide 1 | 1 | 2023 | 148 | 0.050 |
Why?
| | Pancreatitis | 1 | 2003 | 146 | 0.040 |
Why?
| | Rats, Wistar | 1 | 2003 | 449 | 0.040 |
Why?
| | Liver Cirrhosis | 1 | 2024 | 287 | 0.040 |
Why?
| | Personnel Turnover | 1 | 2022 | 40 | 0.040 |
Why?
| | Practice Guidelines as Topic | 2 | 2020 | 1579 | 0.040 |
Why?
| | Cell Death | 1 | 2003 | 382 | 0.040 |
Why?
| | Cholesterol, LDL | 1 | 2023 | 360 | 0.040 |
Why?
| | Reperfusion Injury | 1 | 2004 | 292 | 0.040 |
Why?
| | Troponin | 1 | 2021 | 50 | 0.040 |
Why?
| | Neutrophils | 2 | 2004 | 1123 | 0.040 |
Why?
| | Consensus | 1 | 2023 | 478 | 0.040 |
Why?
| | Organizational Culture | 1 | 2022 | 161 | 0.040 |
Why?
| | Disease Progression | 2 | 2019 | 2857 | 0.040 |
Why?
| | Systole | 1 | 2021 | 181 | 0.040 |
Why?
| | Inpatients | 1 | 2025 | 552 | 0.040 |
Why?
| | Cells, Cultured | 1 | 2008 | 4142 | 0.040 |
Why?
| | Ambulatory Care | 1 | 2025 | 608 | 0.040 |
Why?
| | Genotype | 1 | 2025 | 1844 | 0.040 |
Why?
| | Free Radical Scavengers | 1 | 2020 | 82 | 0.040 |
Why?
| | Cytokines | 1 | 2008 | 2048 | 0.040 |
Why?
| | DNA-Binding Proteins | 1 | 2007 | 1479 | 0.040 |
Why?
| | Sodium Bicarbonate | 1 | 2020 | 47 | 0.040 |
Why?
| | Job Satisfaction | 1 | 2022 | 236 | 0.040 |
Why?
| | Sodium | 1 | 2020 | 198 | 0.040 |
Why?
| | Acetylcysteine | 1 | 2020 | 139 | 0.040 |
Why?
| | Hospitals, High-Volume | 1 | 2019 | 50 | 0.040 |
Why?
| | Exercise Tolerance | 1 | 2021 | 283 | 0.040 |
Why?
| | Cost Savings | 1 | 2019 | 86 | 0.040 |
Why?
| | Endocrinologists | 1 | 2018 | 12 | 0.040 |
Why?
| | Angiotensin Receptor Antagonists | 1 | 2019 | 115 | 0.040 |
Why?
| | Drug Utilization | 1 | 2019 | 167 | 0.040 |
Why?
| | Retreatment | 1 | 2018 | 79 | 0.040 |
Why?
| | Hypertension | 2 | 2018 | 1269 | 0.040 |
Why?
| | Comparative Effectiveness Research | 1 | 2019 | 167 | 0.030 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2019 | 229 | 0.030 |
Why?
| | Rats | 2 | 2004 | 5582 | 0.030 |
Why?
| | Singapore | 1 | 2017 | 27 | 0.030 |
Why?
| | Republic of Korea | 1 | 2017 | 43 | 0.030 |
Why?
| | Transcription Factors | 1 | 2006 | 1731 | 0.030 |
Why?
| | Angina, Unstable | 1 | 2017 | 83 | 0.030 |
Why?
| | Purpura, Thrombotic Thrombocytopenic | 1 | 2017 | 14 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2020 | 1264 | 0.030 |
Why?
| | New Jersey | 1 | 2016 | 16 | 0.030 |
Why?
| | Michigan | 1 | 2016 | 134 | 0.030 |
Why?
| | Glomerular Filtration Rate | 1 | 2020 | 765 | 0.030 |
Why?
| | Aortography | 1 | 2016 | 52 | 0.030 |
Why?
| | Platelet Aggregation | 1 | 2016 | 99 | 0.030 |
Why?
| | Postoperative Care | 1 | 2017 | 286 | 0.030 |
Why?
| | Glucose | 1 | 2020 | 1048 | 0.030 |
Why?
| | Linear Models | 1 | 2017 | 844 | 0.030 |
Why?
| | Guideline Adherence | 1 | 2019 | 586 | 0.030 |
Why?
| | Drug Prescriptions | 1 | 2017 | 287 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2021 | 1742 | 0.030 |
Why?
| | Hirudins | 1 | 2015 | 53 | 0.030 |
Why?
| | Blood Transfusion | 1 | 2017 | 407 | 0.030 |
Why?
| | Protective Factors | 1 | 2014 | 99 | 0.030 |
Why?
| | Blood Coagulation | 1 | 2016 | 274 | 0.030 |
Why?
| | Genetic Predisposition to Disease | 1 | 2022 | 2351 | 0.020 |
Why?
| | Clinical Trials as Topic | 1 | 2019 | 1058 | 0.020 |
Why?
| | Health Policy | 1 | 2016 | 400 | 0.020 |
Why?
| | Blood Flow Velocity | 1 | 2014 | 420 | 0.020 |
Why?
| | Emergencies | 1 | 2013 | 174 | 0.020 |
Why?
| | Lipids | 1 | 2017 | 706 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 2015 | 1368 | 0.020 |
Why?
| | Cost-Benefit Analysis | 1 | 2014 | 640 | 0.020 |
Why?
| | Health Care Costs | 1 | 2014 | 425 | 0.020 |
Why?
| | Kidney Failure, Chronic | 1 | 2017 | 599 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2018 | 2949 | 0.020 |
Why?
| | Models, Biological | 1 | 2017 | 1763 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2022 | 6055 | 0.020 |
Why?
| | Medicare | 1 | 2014 | 902 | 0.020 |
Why?
| | Clofibrate | 1 | 2007 | 3 | 0.020 |
Why?
| | Orphan Nuclear Receptors | 1 | 2007 | 14 | 0.020 |
Why?
| | Hydrocarbons, Fluorinated | 1 | 2007 | 8 | 0.020 |
Why?
| | Peroxisome Proliferator-Activated Receptors | 1 | 2007 | 17 | 0.020 |
Why?
| | Liver X Receptors | 1 | 2007 | 29 | 0.020 |
Why?
| | beta-Cyclodextrins | 1 | 2007 | 32 | 0.020 |
Why?
| | Mice | 1 | 2025 | 18303 | 0.020 |
Why?
| | Fluorocarbons | 1 | 2007 | 119 | 0.010 |
Why?
| | Down-Regulation | 1 | 2007 | 618 | 0.010 |
Why?
| | Physicians | 1 | 2013 | 954 | 0.010 |
Why?
| | Mesenteric Arteries | 1 | 2004 | 17 | 0.010 |
Why?
| | Jejunum | 1 | 2004 | 37 | 0.010 |
Why?
| | Interleukin-10 | 1 | 2006 | 309 | 0.010 |
Why?
| | Telemedicine | 1 | 2013 | 956 | 0.010 |
Why?
| | Gelatin | 1 | 2004 | 56 | 0.010 |
Why?
| | Peroxidase | 1 | 2004 | 168 | 0.010 |
Why?
| | Sulfonamides | 1 | 2007 | 583 | 0.010 |
Why?
| | Microscopy, Fluorescence | 1 | 2004 | 408 | 0.010 |
Why?
| | Enzyme Activation | 1 | 2004 | 762 | 0.010 |
Why?
| | Blotting, Western | 1 | 2004 | 1177 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 2004 | 2524 | 0.010 |
Why?
|
|
Waldo's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|